title: Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy.
abstract: BACKGROUND
  The purpose of the study was to determine the prevalence and associations of clinically relevant fatigue (CRF) in men with biochemically controlled prostate cancer on long-term androgen deprivation therapy (ADT).
  
  
  METHODS
  One hundred and ninety-eight men were surveyed and the prevalence of CRF (Brief Fatigue Inventory score >3) determined. Associations with other measures (Hospital Anxiety and Depression Scale; International Prostate Symptom Score; European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Brief Pain Inventory worst pain; clinical and demographic information) were explored in univariate and multivariate analyses.
  
  
  RESULTS
  Eight-one per cent (160 of 198) of questionnaires were analysable. CRF prevalence was 43% (68 of 160). CRF associations included moderate/severe urinary symptoms, anxiety and medical co-morbidities; the strongest associations were depression [odds ratio (OR) 9.8, 95% confidence interval (CI) 4.3-22.8] and pain (OR 9.2, 95% CI 4.0-21.5). After controlling for other factors, the independent associations were depression (OR 4.7, 95% CI 1.6-14.0) and pain (OR 3.1, 95% CI 1.0-8.9). There was no association with age, disease burden or treatment duration.
  
  
  CONCLUSIONS
  Two-fifths of men with biochemically controlled prostate cancer on long-term ADT report CRF that interferes with function. Management aimed at improving CRF should address depression and pain.
authors: University of Edinburgh, Edinburgh, UK. dawn.storey@ed.ac.uk
authors: D J
authors: DJ
authors: Storey
authors: D B
authors: DB
authors: McLaren
authors: M A
authors: MA
authors: Atkinson
authors: I
authors: I
authors: Butcher
authors: L C
authors: LC
authors: Frew
authors: J F
authors: JF
authors: Smyth
authors: M
authors: M
authors: Sharpe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001007:Anxiety / Q000150:complications; D003430:Cross-Sectional Studies; D003863:Depression / Q000150:complications; D005221:Fatigue / Q000139:chemically induced* / Q000453:epidemiology / Q000209:etiology; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D010146:Pain / Q000150:complications; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D011788:Quality of Life; D057566:Self Report
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone